Q2 EPS Estimate for Ocular Therapeutix Lowered by Analyst

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share estimates for shares of Ocular Therapeutix in a research report issued to clients and investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will post earnings per share of ($0.37) for the quarter, down from their previous estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.48) EPS.

A number of other research firms have also recently weighed in on OCUL. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price objective on the stock. William Blair started coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an “outperform” rating for the company. Needham & Company LLC decreased their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, JMP Securities set a $19.00 target price on Ocular Therapeutix in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and a consensus target price of $16.25.

Ocular Therapeutix Trading Down 4.6 %

NASDAQ:OCUL opened at $7.11 on Thursday. The stock has a 50-day simple moving average of $7.46 and a 200-day simple moving average of $8.29. The stock has a market cap of $1.13 billion, a P/E ratio of -5.39 and a beta of 1.51. Ocular Therapeutix has a 1 year low of $4.79 and a 1 year high of $11.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in Ocular Therapeutix in the 4th quarter valued at approximately $28,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Ocular Therapeutix in the 4th quarter valued at approximately $43,000. AlphaQuest LLC purchased a new stake in shares of Ocular Therapeutix in the fourth quarter valued at approximately $53,000. GAMMA Investing LLC grew its holdings in Ocular Therapeutix by 6,760.0% during the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 8,112 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Ocular Therapeutix by 2,045.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 8,446 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Pravin Dugel sold 21,475 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is owned by insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.